Baritinib inhibits JAK/STAT signal transduction, IFN-γ-induced CXCL10 expression, and immune cell chemotactic activity, indicating its effectiveness for the treatment of SS [73, 74]. The gene discussed is IFNG; the disease is synovial sarcoma.